Eikon Therapeutics, Inc. (NASDAQ:EIKN - Free Report) - HC Wainwright increased their FY2026 earnings estimates for shares of Eikon Therapeutics in a note issued to investors on Thursday, November 12th. HC Wainwright analyst S. Nik now forecasts that the company will earn ($7.11) per share for the year, up from their prior forecast of ($7.40). HC Wainwright currently has a "Buy" rating and a $23.00 target price on the stock. The consensus estimate for Eikon Therapeutics' current full-year earnings is ($7.04) per share. HC Wainwright also issued estimates for Eikon Therapeutics' Q4 2026 earnings at ($1.69) EPS and FY2027 earnings at ($7.50) EPS.
Eikon Therapeutics (NASDAQ:EIKN - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($1.59) EPS for the quarter, beating the consensus estimate of ($1.74) by $0.15.
Other research analysts have also issued research reports about the company. Wall Street Zen upgraded Eikon Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Mizuho upgraded Eikon Therapeutics to a "strong-buy" rating in a report on Wednesday, September 16th. Weiss Ratings raised Eikon Therapeutics from a "sell (e)" rating to a "sell (e+)" rating in a research report on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Finally, Wedbush cut their target price on Eikon Therapeutics from $5.00 to $4.00 and set an "underperform" rating on the stock in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, Eikon Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $24.67.
Get Our Latest Stock Analysis on EIKN
Eikon Therapeutics Stock Performance
EIKN stock opened at $5.98 on Monday. The stock's 50 day simple moving average is $7.53 and its 200 day simple moving average is $10.04. Eikon Therapeutics has a fifty-two week low of $5.01 and a fifty-two week high of $17.40. The company has a market cap of $323.94 million and a P/E ratio of -1.46.
Insider Activity
In other Eikon Therapeutics news, major shareholder Group Iv Gp Lp Column bought 89,200 shares of the firm's stock in a transaction dated Thursday, September 3rd. The stock was bought at an average cost of $11.56 per share, with a total value of $1,031,152.00. Following the completion of the transaction, the insider directly owned 89,200 shares in the company, valued at approximately $1,031,152. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.
Hedge Funds Weigh In On Eikon Therapeutics
Several large investors have recently added to or reduced their stakes in the business. Entropy Technologies LP bought a new position in Eikon Therapeutics in the 3rd quarter valued at about $125,000. State Street Corp increased its holdings in Eikon Therapeutics by 71.9% during the 3rd quarter. State Street Corp now owns 608,838 shares of the company's stock worth $4,895,000 after purchasing an additional 254,745 shares in the last quarter. Alps Advisors Inc. increased its holdings in Eikon Therapeutics by 29.7% during the 3rd quarter. Alps Advisors Inc. now owns 71,255 shares of the company's stock worth $573,000 after purchasing an additional 16,307 shares in the last quarter. Regents of The University of California bought a new stake in Eikon Therapeutics during the 3rd quarter worth approximately $5,106,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Eikon Therapeutics in the second quarter worth approximately $461,000.
Eikon Therapeutics Company Profile
(
Get Free Report)
Eikon Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets. Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eikon Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eikon Therapeutics wasn't on the list.
While Eikon Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.